References

Cancer statistics

10.3322/caac.21332 · 2016 · External reference

Systemic treatment of advanced non-small cell lung cancer

10.1358/dot.2004.40.8.850472 · 2004 · External reference

Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer

10.1016/s0360-3016(01)01685-6 · 2001 · External reference

Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study

10.1016/s0167-8140(03)00119-1 · 2003 · External reference

Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non–small-cell lung carcinoma

10.1016/j.ijrobp.2004.06.260 · 2005 · External reference

Increased 18F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study

10.1016/j.radonc.2009.01.004 · 2009 · External reference

Inflammatory cell recruitment following thoracic irradiation

10.1080/01902140490438915 · 2004 · External reference

Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction

10.7326/0003-4819-118-9-199305010-00006 · 1993 · External reference

Radiation-induced lung injury. Assessment, management, and prevention

2008 · External reference

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors

10.1200/jco.1995.13.10.2606 · 1995 · External reference

Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel

10.1093/jnci/93.23.1806 · 2001 · External reference

Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation

10.1002/1097-0142(19940515)73:10<2549::aid-cncr2820731016>3.0.co;2-n · 1994 · External reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to Gefitinib

10.1056/nejmoa040938 · 2004 · External reference

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

10.1200/jco.2001.19.13.3267 · 2001 · External reference

Erlotinib in previously treated non–small-cell lung cancer

10.1056/nejmoa050753 · 2005 · External reference

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

10.1016/s1470-2045(10)70112-1 · 2010 · External reference

Symptom Improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of canada clinical trials group study BR.21

10.1200/jco.2006.05.8073 · 2006 · External reference

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the trust study

10.1097/jto.0b013e31818ddcaa · 2008 · External reference

Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression

10.1016/j.radonc.2011.05.035 · 2011 · External reference

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

10.1634/theoncologist.10-5-345 · 2005 · External reference

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer

10.3747/co.v18i3.877 · 2011 · External reference

Erlotinib-associated acute pneumonitis: report of two cases

10.1155/2007/832605 · 2007 · External reference

Pulmonary toxicities of biologics: a review

10.1097/cad.0b013e328333d662 · 2010 · External reference

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

10.1186/1471-2407-7-150 · 2007 · External reference

Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®)

10.1191/1078155205jp158cr · 2005 · External reference

Early FDG-PET imaging after radical radiotherapy for non–small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation

10.1016/j.ijrobp.2004.03.036 · 2004 · External reference

A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer

10.1200/jco.2006.10.3747 · 2007 · External reference

Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response

10.1016/j.ijrobp.2008.04.002 · 2008 · External reference

Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung

10.1016/j.ijrobp.2007.01.031 · 2007 · External reference

[18F]-FDG uptake dose–response correlates with radiation pneumonitis in lung cancer patients

10.1016/j.radonc.2012.04.003 · 2012 · External reference

FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin

10.1152/japplphysiol.01429.2005 · 2006 · External reference

Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer

10.1016/j.ijrobp.2004.04.022 · 2004 · External reference

A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer

10.1371/journal.pone.0109560 · 2014 · External reference

Methods for fully automated verification of patient set-up in external beam radiotherapy with polygon shaped fields

10.1088/0031-9155/39/6/006 · 1994 · External reference

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease

10.1038/cti.2016.65 · 2016 · External reference

Gene Ontology annotations: what they mean and where they come from

10.1186/1471-2105-9-s5-s2 · 2008 · External reference

Creating the gene ontology resource: design and implementation

10.1101/gr.180801 · 2001 · External reference

PET and PET-CT imaging in infection and inflammation: Its critical role in assessing complications related to therapeutic interventions in patients with cancer

10.4103/0019-509x.73562 · 2010 · External reference

Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT

10.2967/jnumed.108.057901 · 2009 · External reference

Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis

10.1136/bmjresp-2015-000085 · 2015 · External reference

Up-regulation of the chemokine CCL21 in the skin of subjects exposed to irritants

2004 · External reference

Secondary lymphoid tissue chemokine (CCL21) is upregulated in allergic contact dermatitis

10.1159/000076129 · 2004 · External reference

Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k

10.1634/theoncologist.2009-0055 · 2009 · External reference

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

10.1038/nrc.2016.36 · 2016 · External reference